schizophrenia drug

balloon missed target pop arrows miss failure
Biotech

Boehringer's schizophrenia drug fails trio of phase 3 trials

Boehringer’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials.
Gabrielle Masson Jan 16, 2025 11:58am
schizophrenia mental health brain neurodegenerative

LB Pharma's twist on old Sanofi drug passes schizophrenia test

Jan 8, 2025 7:00am
success failure signposts

Neurocrine's KarXT rival hits in phase 2—but only at low dose

Aug 28, 2024 7:53am
blood pressure heart stethoscope

Karuna's schizophrenia drug clears blood pressure test

Nov 17, 2023 8:52am
A puzzle of the brain with one missing piece

Newron's schizophrenia data boost chances of historic approval

Feb 16, 2023 8:30am
On target clinical trial success bullseye score

Karuna hits goal in schizophrenia phase 3, teeing up 2023 filing

Aug 8, 2022 9:48am